Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi Prices IPO above Range

publication date: Aug 9, 2007
Stock Opens 30% Higher WuXi PharmaTech (WX), the contract research organization (CRO) based in Shanghai, priced its IPO at $14 last night, just above the $11 to $13 range it announced in its prospectus. When trading began this morning, the stock jumped 32% to $18.50. In the early going, WuXi has traded between $18 and $19.49. Two hours into the session, WuXi is holding the $18.50 opening price. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital